LCL-161

LCL-161

CAT N°: 22420
Price:

From 240.00 204.00

LCL-161 is a small molecule Smac mimetic that inhibits multiple inhibitor of apoptosis (IAP) family proteins.{37162} As a single agent, LCL-161 inhibits growth of FLT3-ITD-expressing leukemia cells via induction of apoptosis with IC50 values ranging from 0.5-4 ?M. In vivo, LCL-161 enhances growth inhibition driven by PKC 412 (Item No. 10459) in a mouse Ba/F3-FLT3-ITD-luc+ leukemia xenograft model. It exhibits additive effects with the chemotherapeutic agents doxorubicin (Item No. 15007) and cytarabine (Item No. 16069). LCL-161 also inhibits growth of nilotinib-resistant leukemia cell lines and exhibits synergy with nilotinib (Item No. 10010422) in a Bcr-Abl expressing, 32D.p20-luc+ leukemia mouse xenograft model.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2S-(methylamino)-propanamide
  • Correlated keywords
    • LCL161 FLT-3 FLT3ITD PKC-412 second mitochondrial-derived activator of caspases PKC412 FMS-related tyrosine kinase bearing internal-tandem duplication
  • Product Overview:
    LCL-161 is a small molecule Smac mimetic that inhibits multiple inhibitor of apoptosis (IAP) family proteins.{37162} As a single agent, LCL-161 inhibits growth of FLT3-ITD-expressing leukemia cells via induction of apoptosis with IC50 values ranging from 0.5-4 ?M. In vivo, LCL-161 enhances growth inhibition driven by PKC 412 (Item No. 10459) in a mouse Ba/F3-FLT3-ITD-luc+ leukemia xenograft model. It exhibits additive effects with the chemotherapeutic agents doxorubicin (Item No. 15007) and cytarabine (Item No. 16069). LCL-161 also inhibits growth of nilotinib-resistant leukemia cell lines and exhibits synergy with nilotinib (Item No. 10010422) in a Bcr-Abl expressing, 32D.p20-luc+ leukemia mouse xenograft model.

We also advise you